Dickran Kazandjian, Md
Clinical trials sponsored by Dickran Kazandjian, Md, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new biologic erase traces of myeloma and delay transplant? Results expected Aug 2027 (estimated)
-
Can a new biologic erase traces of myeloma and delay transplant?
Disease control Recruiting nowThis phase 2 trial is testing whether linvoseltamab, an investigational biologic given by infusion, can turn minimal residual disease (MRD) from positive to negative in people with newly diagnosed multiple myeloma. Participants have already received initial combination therapy bu…
Phase 2 • Sponsor: Dickran Kazandjian, MD • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo aims to wipe out hidden myeloma cells
Disease control Recruiting nowThis phase 2 trial tests whether adding linvoseltamab to standard lenalidomide maintenance can eliminate remaining cancer cells in people with multiple myeloma. About 32 participants will receive the combination for up to 24 cycles. The goal is to see if this approach can deepen …
Phase 2 • Sponsor: Dickran Kazandjian, MD • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC